Journal
JOURNAL OF ASSISTED REPRODUCTION AND GENETICS
Volume 34, Issue 9, Pages 1105-1113Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10815-017-0977-4
Keywords
Anti-Mullerian hormone; Mullerian inhibiting substance; Fertility treatment; Contraception; Ovulation induction; Menopause; Fertility preservation; Polycystic ovarian syndrome; Ovarian cancer; Endometrial cancer; AMH agonist; AMH antagonist; AMH analogues
Funding
- Center for Human Reproduction
- Foundation for Reproductive Medicine
- Ferring Innovation Grant
Ask authors/readers for more resources
Members of the transforming growth factor-beta (TGF-beta) superfamily are key regulators of various physiological processes. Anti-Mullerian hormone (AMH) which is also commonly known as Mullerian-inhibiting substance (MIS) is a member of the TGF-beta superfamily and an important regulator of reproductive organ differentiation and ovarian follicular development. While AMH has been used for diagnostic purposes as a biomarker for over 15 years, new potential therapeutic applications of recombinant human AMH analogues are now emerging as pharmacologic agents in reproductive medicine. Therapeutic uses of AMH in gonadal tissue may provide a unique opportunity to address a broad range of reproductive themes, like contraception, ovulation induction, onset of menopause, and fertility preservation, as well as specific disease conditions, such as polycystic ovarian syndrome (PCOS) and cancers of the reproductive tract. This review explores the most promising therapeutic applications for a novel class of drugs known as AMH analogues with agonist and antagonist functions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available